Protagonist Therapeutics, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports the results of the 2022 Annual Meeting of Stockholders held on May 26, 2022. Protagonist Therapeutics, Inc. is a Delaware corporation with its principal executive offices in Newark, California, and its common stock trades on The Nasdaq Stock Market under the symbol PTGX.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Stockholders voted on four proposals at the Annual Meeting:
- Proposal 1 (Election of Directors): Harold E. Selick, Ph.D., and Bryan Giraudo were elected as Class III directors to serve until the 2025 Annual Meeting. Both nominees received significant support, with approximately 27.9 million and 28.1 million votes "For" respectively.
- Proposal 2 (Executive Compensation): The advisory vote to approve the compensation of named executive officers was approved with 35,832,587 votes "For" versus 413,371 "Against."
- Proposal 3 (Frequency of Compensation Votes): Stockholders voted to recommend an annual frequency for future executive compensation votes. The "1 Year" option received 35,578,366 votes, significantly outpacing the "2 Years" and "3 Years" options.
- Proposal 4 (Ratification of Auditors): The selection of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2022, was ratified with 38,667,405 votes "For."
Guidance, Outlook, and Management Commentary
Based on the strong support for an annual vote in Proposal 3, management intends to hold future advisory votes to approve executive compensation annually until the matter is again submitted to stockholders for a vote. No other guidance, risks, or contingencies were disclosed in this specific filing.
Key Facts for Investor Verification
- Confirmation of the new Class III directors' tenure ending in 2025.
- Management's commitment to annual executive compensation advisory votes.
- Ratification of Ernst & Young LLP as the auditor for the 2022 fiscal year.
- High level of stockholder approval for executive compensation (over 98% of votes cast were "For").